Developer docs
API playgroundTry for free, no card

Search company profiles

DermaSensor

Full company profile

uuid00002c3

Namestring
DermaSensor
Legal namestring
DermaSensor, Inc.
Websiteurl
dermasensor.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

DermaSensor, Inc. is a Miami-based medical device company founded in 2009 that develops an FDA-cleared, AI-powered handheld device for non-invasive skin cancer risk assessment at the point of care. The device combines Elastic Scattering Spectroscopy (ESS) — an optical tissue-sampling technique exclusively licensed from Boston University — with a proprietary neural network machine learning algorithm trained on more than 20,000 spectral scans from 4,500+ histologically confirmed skin lesions. It delivers a binary "Investigate Further" or "Monitor" result plus a 1-10 malignancy confidence score in seconds, with 96% sensitivity for melanoma, basal cell carcinoma, and squamous cell carcinoma in pivotal studies. The product is the first FDA-cleared automated device indicated for all three common skin cancers and the first developed specifically for primary care physicians, who currently miss an estimated 18% of skin cancers due to subjective visual examination alone.

The company's commercial strategy targets the 300,000+ U.S. primary care physicians who see suspicious lesions but face 36.5-day average wait times for dermatology referrals. DermaSensor sells through a direct sales motion (demo requests, field sales targeting health systems and multi-site practices) on a subscription model with two tiers — $199/month for up to 5 patients and $399/month for unlimited users and scans — with no upfront capital cost, a 90-day risk-free trial, and bundled customer support, replacement devices, software updates, and cloud storage. Reimbursement friction is mitigated through a partnership with The Reimbursement Group (TRG) covering CPT codes 96999 and 17999. A Physician Finder directory drives patient-side demand. As of late 2025, the device is commercially available in Florida and Pennsylvania with a waitlist in other U.S. states, and the company holds a Class IIb CE Mark enabling European Economic Area commercialization via a recently signed large European distributor partner. DermaSensor has raised $43M in total funding, including a $16M Series B in October 2025, and is led by CEO Cody Simmons with co-founder/Chairman Dr. Maurice Ferre (former CEO of MAKO Surgical, sold to Stryker for $1.65B) and a Scientific Advisory Board that includes the original ESS inventor Dr. Irving Bigio and senior dermatology academic clinicians.

Short descriptiontext

DermaSensor is a Miami-based medical device company that sells an FDA-cleared, AI-powered handheld device using Elastic Scattering Spectroscopy to help primary care physicians non-invasively assess suspicious skin lesions for melanoma, BCC, and SCC at the point of care via a monthly subscription.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMiami, United States
HQ citystring
Miami
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
skin cancer detection, medical diagnostic devices, AI dermatology screening, primary care technology, elastic scattering spectroscopy
Industry1 code
PRIMARYHLALAGAA
Dermatology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code1 code
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Diagnostic Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Device Subscription/Rental
TypeSubscription Recurring
Description

Monthly subscription model for the DermaSensor device. Physicians pay recurring monthly fees to access the device, software, cloud storage, customer support, replacement devices, and software updates. No upfront capital cost; device remains property of DermaSensor.

dermasensor.com
2Professional Services - Reimbursement Support
TypeProfessional Services
Description

Reimbursement guidance services provided through partnership with TRG (The Reimbursement Group) at no cost to customers. Billing support for CPT codes 96999 and 17999 for DermaSensor services.

dermasensor.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Pricing details2 tiers
1Basic tier - Up to 5 patients per month
ModelSubscriptionBilling cadenceMonthly
Notes

$199/month - Includes device, accessories (charging dock, power supply, regional power adapter), software updates, customer support, replacement devices, cloud storage, remote device monitoring, e-learning courses

dermasensor.com
2Premium tier - Unlimited users and scans
ModelSubscriptionBilling cadenceMonthly
Notes

$399/month - All features of basic tier plus unlimited users and scans. Same accessories and support included.

dermasensor.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

DermaSensor develops, manufactures, and distributes an FDA-cleared, AI-powered handheld device that uses Elastic Scattering Spectroscopy (ESS) combined with a proprietary neural network machine learning algorithm to enable primary care physicians to non-invasively evaluate suspicious skin lesions for melanoma, basal cell carcinoma, and squamous cell carcinoma at the point of care. The company sells the device through a monthly subscription model (with tiers at $199 and $399 per month) that includes software updates, cloud storage, replacement devices, customer support, and reimbursement guidance through a partnership with TRG.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 12 values shown
  • 96% sensitivity for detecting all three common skin cancers in pivotal clinical trials
+11 more records
Product overview1 text field

DermaSensor offers a single core product—the FDA-cleared DermaSensor handheld device for AI-powered skin cancer detection in primary care. The device uses Elastic Scattering Spectroscopy combined with a proprietary machine learning algorithm to provide immediate point-of-care risk assessment for melanoma, BCC, and SCC. Supporting services include a Physician Finder directory for patient referrals and reimbursement support through a partnership with TRG (The Reimbursement Group). The company is exploring future EHR integration and next-generation device features including a camera.

Product and service3 records
1DermaSensor Device
CategoryMedical Diagnostic Devices
Description

FDA-cleared, AI-powered handheld skin cancer detection device using Elastic Scattering Spectroscopy to non-invasively evaluate suspicious lesions for melanoma, basal cell carcinoma, and squamous cell carcinoma. Provides immediate point-of-care risk assessment with "Investigate Further" or "Monitor" output plus a 1-10 malignancy score, sold through monthly subscriptions to primary care physicians, health systems, and concierge practices.

2Physician Finder Directory
CategoryPatient Referral Service
Description

Online directory enabling patients to locate healthcare providers who offer DermaSensor-based skin cancer evaluation, searchable by ZIP code, city, or state. Functions as a patient acquisition tool for subscribing physicians.

3Reimbursement Support via TRG Partnership
CategoryRevenue Cycle Support Service
Description

Free reimbursement guidance service provided through partnership with The Reimbursement Group (TRG), including documentation assistance for government and private insurance plans and coding support for CPT codes 96999 and 17999. Bundled with DermaSensor device subscriptions.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-10
Description

Feasibility study collaboration with UK's National Health Service. Marks beginning of global expansion strategy and validates international clinical utility of DermaSensor's technology in single-payer healthcare system.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Partnership provides free reimbursement guidance to DermaSensor customers. TRG offers targeted support tailored to patient payer requirements, documentation help for government and private insurance plans, and coding guidance including CPT codes 96999 and 17999.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Canadian developer of the Verisante Aura, a Raman spectroscopy-based device for rapid skin lesion assessment. Uses optical spectroscopy analogous to DermaSensor's ESS approach, making it a technology analog and direct competitor in non-invasive skin cancer detection.

TypeDirect peer
Description

UK-based AI dermatology company whose DERM autonomous skin cancer detection platform is used in NHS pathways. Most direct head-to-head competitor to DermaSensor, applying AI to triage suspicious lesions without requiring dermatologist review at the front line.

TypeDirect peer
Description

US leader in dermatology imaging systems (VECTRA, IntelliStudio) used for skin documentation and AI-assisted analysis. Established peer providing imaging infrastructure that overlaps with DermaSensor's point-of-care capture workflow.

TypeDirect peer
Description

Developer of DermEngine, an AI dermatology imaging and analytics platform used by clinics and teledermatology services. Competes with DermaSensor in AI-assisted skin lesion evaluation, particularly in teledermatology workflows.

TypeDirect peer
Description

Public US company (DMTK) offering the DermTech Melanoma Test, an adhesive patch genomic assay for skin cancer risk. Closest US-listed peer working on non-invasive, point-of-care skin cancer detection with payer coverage.

TypeBroad incumbent
Description

Incumbent dermoscopy device maker supplying handheld skin examination tools to dermatologists globally. Represents the established optical examination workflow that DermaSensor aims to supplement in primary care settings.

TypeBroad incumbent
Description

Maker of VivaScope confocal microscopy systems for non-invasive cellular-level skin imaging in dermatology practices. Competes in advanced non-invasive skin lesion evaluation but operates in a higher-priced specialist niche rather than primary care.

TypeEmerging player
Description

Successor to Mela Sciences (MelaFind), focused on dermatology devices and clinic services. Historically the most direct US skin cancer detection device analog and a useful comparator for the regulatory and reimbursement trajectory of such products.

TypeDirect peer
Description

German maker of FotoFinder body mapping and AI mole analysis systems widely used by dermatologists. Closest established peer in AI-assisted dermoscopic imaging and total body photography for skin cancer detection.

TypeDirect peer
Description

Smartphone-based AI skin lesion assessment app serving consumer and clinician segments across Europe and emerging markets. Directly competes on the AI skin cancer detection value proposition with a lower-cost, software-only delivery model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DermaSensor

Medical Diagnostic Devicesdermasensor.com

DermaSensor is a Miami-based medical device company that sells an FDA-cleared, AI-powered handheld device using Elastic Scattering Spectroscopy to help primary care physicians non-invasively assess suspicious skin lesions for melanoma, BCC, and SCC at the point of care via a monthly subscription.

What DermaSensor does

DermaSensor, Inc. is a Miami-based medical device company founded in 2009 that develops an FDA-cleared, AI-powered handheld device for non-invasive skin cancer risk assessment at the point of care. The device combines Elastic Scattering Spectroscopy (ESS) — an optical tissue-sampling technique exclusively licensed from Boston University — with a proprietary neural network machine learning algorithm trained on more than 20,000 spectral scans from 4,500+ histologically confirmed skin lesions. It delivers a binary "Investigate Further" or "Monitor" result plus a 1-10 malignancy confidence score in seconds, with 96% sensitivity for melanoma, basal cell carcinoma, and squamous cell carcinoma in pivotal studies. The product is the first FDA-cleared automated device indicated for all three common skin cancers and the first developed specifically for primary care physicians, who currently miss an estimated 18% of skin cancers due to subjective visual examination alone.

The company's commercial strategy targets the 300,000+ U.S. primary care physicians who see suspicious lesions but face 36.5-day average wait times for dermatology referrals. DermaSensor sells through a direct sales motion (demo requests, field sales targeting health systems and multi-site practices) on a subscription model with two tiers — $199/month for up to 5 patients and $399/month for unlimited users and scans — with no upfront capital cost, a 90-day risk-free trial, and bundled customer support, replacement devices, software updates, and cloud storage. Reimbursement friction is mitigated through a partnership with The Reimbursement Group (TRG) covering CPT codes 96999 and 17999. A Physician Finder directory drives patient-side demand. As of late 2025, the device is commercially available in Florida and Pennsylvania with a waitlist in other U.S. states, and the company holds a Class IIb CE Mark enabling European Economic Area commercialization via a recently signed large European distributor partner. DermaSensor has raised $43M in total funding, including a $16M Series B in October 2025, and is led by CEO Cody Simmons with co-founder/Chairman Dr. Maurice Ferre (former CEO of MAKO Surgical, sold to Stryker for $1.65B) and a Scientific Advisory Board that includes the original ESS inventor Dr. Irving Bigio and senior dermatology academic clinicians.

DermaSensor firmographics

Firmographics
Name
DermaSensor
Legal name
DermaSensor, Inc.
Website
https://dermasensor.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
DermaSensor is a Miami-based medical device company that sells an FDA-cleared, AI-powered handheld device using Elastic Scattering Spectroscopy to help primary care physicians non-invasively assess suspicious skin lesions for melanoma, BCC, and SCC at the point of care via a monthly subscription.
Ownership category
akta.pro rank

DermaSensor industry classification

Industry
Product category
Medical Diagnostic Devices
NAICS
Medical and Diagnostic Laboratories (62151)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLALAGAA
Dermatology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Skin cancer detection
  • Medical diagnostic devices
  • AI dermatology screening
  • Primary care technology
  • Elastic scattering spectroscopy

Where DermaSensor is headquartered

Location

Headquarters

HQ city
Miami
HQ country
United States
HQ region
North America

Offices2 records

Markets served

DermaSensor business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Device Subscription/Rental: Monthly subscription model for the DermaSensor device. Physicians pay recurring monthly fees to access the device, software, cloud storage, customer support, replacement devices, and software updates. No upfront capital cost; device remains property of DermaSensor.
  2. Professional Services - Reimbursement Support: Reimbursement guidance services provided through partnership with TRG (The Reimbursement Group) at no cost to customers. Billing support for CPT codes 96999 and 17999 for DermaSensor services.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyBasic tier - Up to 5 patients per month
SubscriptionMonthlyPremium tier - Unlimited users and scans

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

DermaSensor product offering

Product offering

Core offering

DermaSensor develops, manufactures, and distributes an FDA-cleared, AI-powered handheld device that uses Elastic Scattering Spectroscopy (ESS) combined with a proprietary neural network machine learning algorithm to enable primary care physicians to non-invasively evaluate suspicious skin lesions for melanoma, basal cell carcinoma, and squamous cell carcinoma at the point of care. The company sells the device through a monthly subscription model (with tiers at $199 and $399 per month) that includes software updates, cloud storage, replacement devices, customer support, and reimbursement guidance through a partnership with TRG.

Product overview

DermaSensor offers a single core product—the FDA-cleared DermaSensor handheld device for AI-powered skin cancer detection in primary care. The device uses Elastic Scattering Spectroscopy combined with a proprietary machine learning algorithm to provide immediate point-of-care risk assessment for melanoma, BCC, and SCC. Supporting services include a Physician Finder directory for patient referrals and reimbursement support through a partnership with TRG (The Reimbursement Group). The company is exploring future EHR integration and next-generation device features including a camera.

Differentiator

Problem solved

Functional benefit

Products and services

  • DermaSensor Device FDA-cleared, AI-powered handheld skin cancer detection device using Elastic Scattering Spectroscopy to non-invasively evaluate suspicious lesions for melanoma, basal cell carcinoma, and squamous cell carcinoma. Provides immediate point-of-care risk assessment with "Investigate Further" or "Monitor" output plus a 1-10 malignancy score, sold through monthly subscriptions to primary care physicians, health systems, and concierge practices.
  • Physician Finder Directory Online directory enabling patients to locate healthcare providers who offer DermaSensor-based skin cancer evaluation, searchable by ZIP code, city, or state. Functions as a patient acquisition tool for subscribing physicians.
  • Reimbursement Support via TRG Partnership Free reimbursement guidance service provided through partnership with The Reimbursement Group (TRG), including documentation assistance for government and private insurance plans and coding support for CPT codes 96999 and 17999. Bundled with DermaSensor device subscriptions.

Quantifiable outcome

  • 96% sensitivity for detecting all three common skin cancers in pivotal clinical trials
  • +11 more outcomes

Companies that use DermaSensor

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles4 records

DermaSensor technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

DermaSensor partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • UK National Health Service (NHS)flagshipStrategic or Co-development Partner · 10 June 2026Feasibility study collaboration with UK's National Health Service. Marks beginning of global expansion strategy and validates international clinical utility of DermaSensor's technology in single-payer healthcare system.
  • TRG (The Reimbursement Group)coreImplementation/ SI/ Consulting PartnerPartnership provides free reimbursement guidance to DermaSensor customers. TRG offers targeted support tailored to patient payer requirements, documentation help for government and private insurance plans, and coding guidance including CPT codes 96999 and 17999.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

DermaSensor competitors and assessment

Company assessment

Direct peers

  • Verisante Technology: Canadian developer of the Verisante Aura, a Raman spectroscopy-based device for rapid skin lesion assessment. Uses optical spectroscopy analogous to DermaSensor's ESS approach, making it a technology analog and direct competitor in non-invasive skin cancer detection.
  • Skin Analytics: UK-based AI dermatology company whose DERM autonomous skin cancer detection platform is used in NHS pathways. Most direct head-to-head competitor to DermaSensor, applying AI to triage suspicious lesions without requiring dermatologist review at the front line.
  • Canfield Scientific: US leader in dermatology imaging systems (VECTRA, IntelliStudio) used for skin documentation and AI-assisted analysis. Established peer providing imaging infrastructure that overlaps with DermaSensor's point-of-care capture workflow.
  • MetaOptima Technology: Developer of DermEngine, an AI dermatology imaging and analytics platform used by clinics and teledermatology services. Competes with DermaSensor in AI-assisted skin lesion evaluation, particularly in teledermatology workflows.
  • DermTech: Public US company (DMTK) offering the DermTech Melanoma Test, an adhesive patch genomic assay for skin cancer risk. Closest US-listed peer working on non-invasive, point-of-care skin cancer detection with payer coverage.
  • FotoFinder Systems: German maker of FotoFinder body mapping and AI mole analysis systems widely used by dermatologists. Closest established peer in AI-assisted dermoscopic imaging and total body photography for skin cancer detection.
  • SkinVision: Smartphone-based AI skin lesion assessment app serving consumer and clinician segments across Europe and emerging markets. Directly competes on the AI skin cancer detection value proposition with a lower-cost, software-only delivery model.

Broad incumbents

  • DermLite (3Gen): Incumbent dermoscopy device maker supplying handheld skin examination tools to dermatologists globally. Represents the established optical examination workflow that DermaSensor aims to supplement in primary care settings.
  • Caliber Imaging & Diagnostics: Maker of VivaScope confocal microscopy systems for non-invasive cellular-level skin imaging in dermatology practices. Competes in advanced non-invasive skin lesion evaluation but operates in a higher-priced specialist niche rather than primary care.

Emerging players

  • STRATA Skin Sciences: Successor to Mela Sciences (MelaFind), focused on dermatology devices and clinic services. Historically the most direct US skin cancer detection device analog and a useful comparator for the regulatory and reimbursement trajectory of such products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

DermaSensor social profiles

Digital presence

DermaSensor compliance and trust

Trust signal

Compliance2 records

DermaSensor financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DermaSensor leadership team

Management profile

Number of profiles

Profiles15 records

DermaSensor subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

DermaSensor funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DermaSensor M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DermaSensor

What does DermaSensor do?

DermaSensor develops, manufactures, and distributes an FDA-cleared, AI-powered handheld device that uses Elastic Scattering Spectroscopy (ESS) combined with a proprietary neural network machine learning algorithm to enable primary care physicians to non-invasively evaluate suspicious skin lesions for melanoma, basal cell carcinoma, and squamous cell carcinoma at the point of care. The company sells the device through a monthly subscription model (with tiers at $199 and $399 per month) that includes software updates, cloud storage, replacement devices, customer support, and reimbursement guidance through a partnership with TRG.

Is DermaSensor a public or private company?

DermaSensor is a private company. It is classified as venture growth investor backed and is currently operating.

When was DermaSensor founded?

DermaSensor was founded in 2009. It employs 11 to 50 people.

Where is DermaSensor based?

DermaSensor is headquartered in Miami, United States, in the North America region.

How does DermaSensor make money?

Two revenue lines are on record. Device Subscription/Rental is the primary driver. The others are professional Services - Reimbursement Support.

Who are DermaSensor's main competitors?

Direct peers on record are Verisante Technology, Skin Analytics, Canfield Scientific, MetaOptima Technology, DermTech, FotoFinder Systems and SkinVision. Broad incumbents are DermLite (3Gen) and Caliber Imaging & Diagnostics. STRATA Skin Sciences is listed as an emerging player.

Does DermaSensor have an API?

No public API is recorded for DermaSensor.

What industry is DermaSensor in?

DermaSensor's product category is Medical Diagnostic Devices. Its primary akta.pro industry code is HLALAGAA, Dermatology Telemedicine Platforms. Its NAICS code is 62151 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
In VivoDermaSensor Skin Lesion Assessment Tool, Samsung Sleep Apnea Feature Among New FDA ClassificationsThe FDA codified four additional device classifications, including a Samsung Galaxy Watch sleep apnea alert and DermaSensor's skin lesion assessment tool, completing the transition from De Novo to Class II status. The orders, posted Oct. 29 and published Oct. 30 in the Federal Register, allow similar devices to be cleared via the 510(k) process.BarchartHog See Monday Weakness, with Cash Losses ContinuingDermaSensor, maker of an FDA-cleared AI device for skin cancer detection, opened a Wefunder investment round to retail investors. The company has raised $48 million and reports 96% sensitivity in detecting common skin cancers. It targets an $8 billion market and has launched in Germany.Refresh MiamiDermaSensor raises $5M and opens community round on Wefunder amid commercial growthDermaSensor raised $5 million in a Series B extension and opened a Wefunder community round, bringing total investment to $48 million. The company also closed four new partnerships to expand its FDA-cleared AI skin-cancer detection device. CEO Cody Simmons said the company aims to reach $100 million in annual recurring revenue by 2031.Medical Device NetworkDermaSensor completes $5m fundraise following new partnership quadrupletDermaSensor closed a $5M Series B extension, bringing total funds to about $48M. The financing followed four new partnerships, including a supplier agreement with Henry Schein and a VA reseller deal. The company's AI-based skin cancer diagnostic has 96% sensitivity in published studies.Straits ResearchDigital Dermatoscopes: Imaging Devices & Connected DermatologyThe digital dermatoscopy market is evolving toward smartphone-connected and AI-integrated systems to address rising melanoma cases, with recent regulatory approvals and funding rounds highlighting key industry developments. Notable events include DermaSensor securing a CE Mark and Series B financing, MetaOptima receiving government support for its AI imaging system, and GHO Capital acquiring a majority stake in FotoFinder Systems.Dermatology TimesDermaSensor Increases Confidence and Accuracy in Melanoma DetectionDermaSensor announced two newly published clinical studies on November 4, 2025, demonstrating the effectiveness of its AI-powered elastic scattering spectroscopy device for melanoma detection among primary care physicians.Boston UniversityWith New Technology and Innovative Treatments, BU Cancer Research Is Saving LivesBoston University researchers have developed and successfully commercialized multiple cancer detection and treatment technologies, including DermaSensor, an FDA-cleared skin cancer detection device that has scanned tens of thousands of lesions and detected 2,000 skin cancers in its first year. BU researchers also codeveloped the Percepta lung cancer test (acquired and commercialized by Veracyte), contributed to chemotherapy drug Abraxane, and developed UltraView, a prostate cancer microscope now being produced by Vibronix and available in China. A team led by Julie Palmer influenced national screening guidelines by demonstrating that a simple smoking duration cutoff would significantly increase lung cancer screening eligibility for Black women, reducing racial disparities in care.BioWorldDermasensor receives CE mark for skin cancer detection deviceDermasensor Inc. received CE mark approval for its handheld skin cancer detection device, which uses spectroscopy and AI to test suspicious skin lesions in real time. The device helps healthcare professionals decide whether further investigation is needed, joining other AI-based tools entering the European market.MassDeviceDermaSensor wins CE mark for skin cancer detection deviceMiami-based DermaSensor announced it received Class IIb CE mark approval for its AI-powered handheld skin cancer detection device, enabling commercialization across Europe as part of its global expansion strategy. The device uses optical spectroscopy to non-invasively evaluate lesions and provides immediate results using an FDA-cleared algorithm, having already received FDA clearance in January 2025. The company also announced a feasibility study with the UK's National Health Service and a commercial partnership with a large European distributor who invested $5 million in DermaSensor's recent Series B financing.Refresh MiamiDermaSensor is expanding internationally with its skin-cancer detection device, receives $5M investmentDermaSensor, a Miami-based health technology company, has received Class IIb CE Mark certification for its AI-powered handheld skin cancer detection device, enabling commercialization across the European Economic Area. The certification follows FDA authorization in 2024 and years of clinical validation involving over 40 study sites and nine published clinical studies. A major European commercial partner invested $5 million in the company's Series B round to accelerate market access in several of Europe's largest healthcare markets.